Ketamine Use for Sedation in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19) Infection: A Case Series

Case Series

Austin Crit Care Case Rep. 2023; 7(1): 1041.

Ketamine Use for Sedation in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19) Infection: A Case Series

Dania Ghaziri¹; Salwa A Koubaissi² and Imad Bouakl²

¹Department of Pharmacy, American University of Beirut Medical Center, Lebanon

²Pulmonary and Critical Care Division, Department of Internal Medicine, American University of Beirut Medical Center, Lebanon

*Corresponding author: Bouakl I Pulmonary and Critical Care Division, Department of Internal Medicine, American University of Beirut Medical Center, Lebanon

Received: January 24, 2023; Accepted: March 02, 2023; Published: March 09, 2023

Abstract

Introduction: Ketamine has been previously used as an add-on analgesic and a sedative agents for the treatment of critically ill surgical patients, resulting in a reduced opioid consumption. During the Coronavirus Disease 2019 (COVID-19) pandemic, a surge of critically ill patients with Acute Respiratory Distress Syndrome (ARDS) requiring mechanical ventilation with deep sedation and paralysis lead to the overuse of first line sedative medications like benzodiazepines and Propofol, exposing them to serious shortages, especially in view of worsening national economic crisis. This dilemma pushed the critical care teams to explore new medications for sedation, resulting in shifting away from the first line therapies to the use of other sedatives, like Ketamine. We describe our experience using Ketamineto maintain an adequate sedation when Midazolam was not available and Propofol contraindicated.

Methods: Ketamine was used on four critically ill patients with severe COVID-19 ARDS requiring paralysis. We focused on vital signs variation and quality of sedation during Ketamine use in comparison to Midazolam/Propofol. During the transition period from Midazolam/Propofol to Ketamine, our patients had an acute increase in blood pressure, respiratory rate and heart rate, a drop in their oxygen saturation with ventilator dyssynchrony. Other deteriorations witnessed included new respiratory acidosis and cardiac arrhythmia.

Discussion: In comparison to previous successful uses of Ketamine in the Intensive Care Unit ICU, its limited efficacy in our population could be explained by the requirement for neuro-muscular blockade, the high ventilatory drive and the fact that it was used alone.

Conclusion: Our experience with Ketamine during drug shortage of first-line sedatives in critically ill patients with COVID-19 ARDS was shown to be insufficient when used alone as an alternative sedative agent compared to Propofol and Midazolam. Further studies with larger sample size are advised before drawing a final conclusion.

Keywords: Ketamine; Critical care; First-line sedative; Synchrony

Introduction

During the Coronavirus Disease 2019 (COVID-19) pandemic, severely ill patients with severe lung injury and respiratory difficulties were admitted to the Intensive Care Unit ICU and put on ventilators (breathing machine) to be able to breathe. Mega doses of sedatives (medications that calm and tranquilize patients) used to help patients tolerate the ventilator were massively used worldwide exposing them to severe shortage. Nationally, that came on top of an economic crisis causing a total depletion of the first line classical sedatives that we usually use in the ICU (Midazolam and Propofol). We were left with Ketamine, a sedative known to be successfully used in the ICU, however, at low doses and always combined with other pain medications and sedatives; but never alone. Sequentially, we had to use very high doses in order to achieve the same level of comfort for patients. We started Ketamine on four patients and, as we were going up with the dose, we noticed that patients were becoming more agitated, experienced significant elevation in blood pressure, heart rate and respiratory rate. They were also not able to breathe properly through the ventilator and the amount of oxygen was dropping in their blood and lungs. Because of this instability, we had to immediately stop Ketamine. Luckily, we received a stock of Midazolam and were able to resume proper sedation and stability for patients. We assume that, failing with Ketamine, is due to the severity of illness of our patients, who required very high doses of sedatives that Ketamine couldn’t achieve without complications; and very high ventilator settings. We concluded that Ketamine, used alone, can not to assure the comfort of severely ill COVID-19 patients on ventilators. Nevertheless, our sample size is small and before reaching a final conclusion, further studies on a larger sample size are needed.

Ketamine has previously been used as an analgesic and a sedative agent for the treatment of critically ill surgical patients, resulting in reduced opioid consumption [1]. The addition of Ketamine to Propofol for procedural sedation in the emergency department has also been described as effective, safe, and satisfying for the providers [2]. During the Coronavirus Disease 2019 (COVID-19) pandemic, a surge of critically ill patients with Acute Respiratory Distress Syndrome (ARDS) requiring mechanical ventilation with deep sedation and paralysis, and where it was impossible to apply the standard light sedation guidelines [3], lead to the overuse of first line sedative medications like benzodiazepines and Propofol, worldwide [4-6] and in Lebanon, resulting in serious shortages [7], especially in view of the economic crisis that hit the country [8]. This dilemma pushed the critical care team to explore new medications for sedation, resulting in a shift away from these first line therapies to the use of other sedatives, like Ketamine. It has already been established that Ketamine can be used as adjunct to high doses of benzodiazepines or Propofol in COVID-19 patients [9,10].

However, due to severe shortages, and for a short period of time, Ketamine was used at the American University of Beirut Medical Center as the main sedative agent (with or without very low doses of benzodiazepines). We aim to describe our experience in the use of Ketamine to maintain adequate sedation either alone or in combination with very low doses of Midazolam (during periods of shortage), when Propofol was contraindicated due to adverse reactions and at a time of severe shortage of Midazolam.

We conducted a retrospective case series on four criticallyill patients with severe COVID-19 ARDS, to describe our experience with Ketamine use as the main or sole sedative in terms of baseline characteristics like vital signs variation, oxygen saturation, Richmond Agitation Sedation Scale (RASS) variation and synchrony with ventilator during Ketamine use.

Cases

A total of four patients who were admitted to our Intensive Care Unit (ICU) were prescribed Ketamine. The median age was 66 years (54-66.5) and the sex distribution was 3 males and 1 female. They were all intubated due to ARDS secondary to COVID-19 infection. Three out of the 4 had previously been paralyzed with Rocuronium which had to be withheld once the switch to Ketamine was decided awaiting the achievement of deep sedation. In terms of paincontrol, they were all on very high rates of Fentanyl (reaching 300 microgram/hour). In all 4 patients, Propofol (reaching 30 microgram/kg/min), was used for sedation but due to elevated triglyceride levels, it had to be stopped. This imposed switching to the only available sedative at that time: Ketamine. Meanwhile, Fentanyl was kept at the same rate. Ketamine rate ranged from 0.2 mg/kg/hour to 4.5mg/kg/hour. Patients were started at the rate of 0.2 mg/kg/hour and up titration was quick, to achieve same RASS and ventilator synchrony. With the rapid up-titration of Ketamine, there was a statistically significant increase in the blood pressure, heart rate and respiratory rate of the patients when the shift from Propofol to Ketamine was done (Table 1) (Figures 1 & 2).